» Articles » PMID: 12721288

BCL-2 and BCL-XL Restrict Lineage Choice During Hematopoietic Differentiation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2003 May 2
PMID 12721288
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Differentiation of hematopoietic cells from multipotential progenitors is regulated by multiple growth factors and cytokines. A prominent feature of these soluble factors is promotion of cell survival, in part mediated by expression of either of the anti-apoptotic proteins, BCL-2 and BCL-XL. The complex expression pattern of these frequently redundant survival factors during hematopoiesis may indicate a role in lineage determination. To investigate the latter possibility, we analyzed factor-dependent cell-Patersen (FDCP)-Mix multipotent progenitor cells in which we stably expressed BCL-2 or BCL-XL. Each factor maintained complete survival of interleukin-3 (IL-3)-deprived FDCP-Mix cells but, unexpectedly, directed FDCP-Mix cells along restricted and divergent differentiation pathways. Thus, IL-3-deprived FDCP-Mix BCL-2 cells differentiated exclusively to granulocytes and monocytes/macrophages, whereas FDCP-Mix BCL-XL cells became erythroid. FDCP-Mix BCL-2 cells grown in IL-3 were distinguished from FDCP-Mix and FDCP-Mix BCL-XL cells by a striking reduction in cellular levels of Raf-1 protein. Replacement of the BCL-2 BH4 domain with the related BCL-XL BH4 sequence resulted in a switch of FDCP-Mix BCL-2 cells to erythroid fate accompanied by persistence of Raf-1 protein expression. Moreover, enforced expression of Raf-1 redirected FDCP-Mix BCL-2 cells to an erythroid fate, and prohibited generation of myeloid cells. These results identify novel roles for BCL-2 and BCL-XL in cell fate decisions beyond cell survival. These effects are associated with differential regulation of Raf-1 expression, perhaps involving the previously identified interaction between BCL-2-BH4 and the catalytic domain of Raf-1.

Citing Articles

Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function.

Perez-Serna A, Guzman-Llorens D, Dos Santos R, Marroqui L Biomedicines. 2025; 13(1).

PMID: 39857806 PMC: 11760435. DOI: 10.3390/biomedicines13010223.


Anti-apoptotic protein Bcl-2 contributes to the determination of reserve cells during myogenic differentiation of C2C12 cells.

Nagata Y, Tomimori J, Hagiwara T In Vitro Cell Dev Biol Anim. 2024; 60(7):760-770.

PMID: 38619740 DOI: 10.1007/s11626-024-00905-3.


Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Leo I, Aswad L, Stahl M, Kunold E, Post F, Erkers T Nat Commun. 2022; 13(1):1691.

PMID: 35354797 PMC: 8967900. DOI: 10.1038/s41467-022-29224-5.


The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells.

Opydo-Chanek M, Cichon I, Rak A, Kolaczkowska E, Mazur L Invest New Drugs. 2020; 38(6):1664-1676.

PMID: 32367199 PMC: 7575496. DOI: 10.1007/s10637-020-00931-4.


Folliculin Interacting Protein 1 Maintains Metabolic Homeostasis during B Cell Development by Modulating AMPK, mTORC1, and TFE3.

Ramirez J, Iwata T, Park H, Tsang M, Kang J, Cui K J Immunol. 2019; 203(11):2899-2908.

PMID: 31676673 PMC: 6864314. DOI: 10.4049/jimmunol.1900395.